NIKKEI 225
39,229.33 -437.74 (-1.10%) HANG SENG
17,813.69 -276.24 (-1.53%) CRUDE OIL
80.52 -0.38 (-0.47%) GOLD FUTURES
2,309.90 -3.30 (-0.14%) DOW
39,127.80 +15.64 (+0.04%) Bitcoin GBP
48,237.43 -1,024.82 (-2.08%)
VKTX Sep 2024 40.000 call
| Previous close | 17.80 |
| Open | 12.50 |
| Bid | 11.90 |
| Ask | 12.60 |
| Strike | 40.00 |
| Expiry date | 2024-09-20 |
| Day's range | 12.08 - 12.50 |
| Contract range | N/A |
| Volume | |
| Open interest | 45 |
ZacksViking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $47.39, denoting a -0.86% change from the preceding trading day.
PR NewswireViking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association
Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of preclinical data from a series of internally developed dual agonists of the amylin and calcitonin receptors at the 84th Scientific Sessions of the American Diabetes Association. The presentation highlights the effects of treatment on body weight, food intake and metabolic profile in h
ZacksWhy Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $50.43, marking a -0.41% move from the previous day.
